← 產業報告目錄

IV Equipment Market by Type (IV Catheter, IV Administration Set, Needle-free Connectors), Application (Medication Administration, Parenteral Nutrition, Diagnostic Testing, Blood & Blood Product Transfusion), End User (Hospital) - Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-02-04頁數 425報告編號 MD5311

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global IV equipment market is projected to reach USD 23.92 billion by 2031 from USD 17.82 billion in 2026, growing at a CAGR of 6.1% during the forecast period. The demand for IV equipment is growing steadily, driven by the rising prevalence of chronic diseases and increasing hospitalizations worldwide. The growing adoption of IV therapy for medication administration, hydration, and nutrition, along with the shift toward home-based and outpatient care, is boosting product utilization. Hospitals and clinics are prioritizing high-quality, safe, and user-friendly IV devices to ensure accurate drug delivery and patient safety. Technological innovations, such as needle-free connectors, smart infusion pumps, and compatible multi-parameter IV systems, are further enhancing market adoption. Moreover, expanding healthcare infrastructure in emerging economies and favorable government initiatives promoting modern healthcare practices are expected to sustain strong market growth in the coming years. “By type, the needle-free connectors & extension sets segment is projected to grow significantly during the forecast period.” Based on type, needle-free connectors & extension sets are the fastest-growing segment in the IV equipment market, driven by their enhanced safety, ease of use, and ability to significantly reduce the risk of infections and needlestick injuries. These connectors streamline medication administration, reduce contamination, and improve workflow efficiency in hospitals, clinics, and home care settings. Their growing adoption is also supported by stringent infection control regulations and increasing awareness among healthcare providers about patient safety, making them a highly preferred choice in modern healthcare facilities. “By application, the medication administration segment held the largest market share in 2025.” By application, medication administration holds the largest market share in the IV equipment market, as IV therapy allows drugs to be delivered directly into the bloodstream, ensuring rapid onset of action, precise dosing, and optimal therapeutic effectiveness. This application is particularly critical in intensive care units, chemotherapy treatments, pain management, and severe infection management, where timely and accurate drug delivery can significantly improve patient outcomes. The growing prevalence of chronic and acute diseases, along with increasing hospital admissions, continues to drive the demand for IV-based medication administration. “By region, North America accounted for the largest market share in 2025.” The IV equipment market is segmented into North America, Europe, Latin America, the Asia Pacific, and the Middle East & Africa. North America leads the global IV equipment market. This dominance is attributed to the high prevalence of chronic diseases, well-established healthcare infrastructure, and rapid adoption of advanced medical technologies. Additionally, the strong presence of key market players, increased healthcare spending, and growing demand for advanced infusion systems in hospitals and home healthcare settings further contribute to the region’s leading market position. A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1 (35%), Tier 2 (40%), and Tier 3 (25%) • By Designation: Directors (25%), Managers (50%), and Others (25%) • By Region: North America (35%), Europe (30%), the Asia Pacific (15%), and the Rest of the World (20%) The prominent players in the IV equipment market are Becton, Dickinson and Company (US), B. Braun SE (Germany), Fresenius SE & Co. KGaA (Germany), ICU Medical, Inc. (US), Terumo Corporation (Japan), Moog Inc. (US), Teleflex Incorporated (US), Cardinal Health (US), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Baxter (US), Avanos Medical, Inc. (US), Nipro (Japan), JMS Co., Ltd. (Japan), Vygon (France), and Micrel Medical Devices SA (Greece), among others. Research Coverage This report analyzes the IV equipment market by type, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets by their individual growth trends and forecasts market segment revenues across five main regions (and the respective countries in these regions). Reasons to Buy the Report The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market presence. This report provides insights into the following pointers: • Analysis of key drivers (rising disease burden and the subsequent surge in the geriatric population globally as well as the shift toward home and ambulatory infusion), restraints (product recalls and failures), opportunities (untapped growth potential in emerging markets), and challenges (vendor collaborations) influencing the growth of the IV equipment market. • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the IV equipment market. • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product developments in the IV equipment market. • Market Development: Comprehensive information on lucrative emerging regions. • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the IV equipment market. • Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
目錄 Table of Contents
1 INTRODUCTION 34 1.1 STUDY OBJECTIVES 34 1.2 MARKET DEFINITION 34 1.3 STUDY SCOPE 35 1.3.1 SEGMENTS CONSIDERED & GEOGRAPHICAL SCOPE 35 1.3.2 INCLUSIONS & EXCLUSIONS 36 1.3.3 YEARS CONSIDERED 37 1.4 CURRENCY CONSIDERED 37 1.5 STAKEHOLDERS 38 1.6 SUMMARY OF CHANGES 38 2 EXECUTIVE SUMMARY 40 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 40 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 41 2.3 DISRUPTIVE TRENDS IN IV EQUIPMENT MARKET 42 2.4 HIGH-GROWTH SEGMENTS 43 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 44 3 PREMIUM INSIGHTS 45 3.1 IV EQUIPMENT MARKET OVERVIEW 45 3.2 ASIA PACIFIC: IV EQUIPMENT MARKET, BY COUNTRY AND END USER 46 3.3 GEOGRAPHIC SNAPSHOT OF IV EQUIPMENT MARKET 47 4 MARKET OVERVIEW 48 4.1 INTRODUCTION 48 4.2 MARKET DYNAMICS 48 4.2.1 DRIVERS 49 4.2.1.1 Rising disease burden and subsequent surge in geriatric population globally 49 4.2.1.2 Shift toward home and ambulatory infusion 49 4.2.1.3 Smart pumps, improved safety features, and precision infusion systems 50 4.2.2 RESTRAINTS 50 4.2.2.1 Product recalls and failures 50 4.2.2.2 Infection and complication risk associated with IV therapy 51 4.2.3 OPPORTUNITIES 51 4.2.3.1 Untapped growth potential in emerging markets 51 4.2.3.2 Technological advancements and vendor collaborations 52   4.2.4 CHALLENGES 52 4.2.4.1 Device reliability, maintenance requirements, and user-related errors 52 4.3 UNMET NEEDS & WHITE SPACES 53 4.3.1 UNMET NEEDS IN IV EQUIPMENT MARKET 53 4.3.1.1 Interoperable & smart IV systems 53 4.3.1.2 Affordable, reliable equipment for emerging markets 53 4.3.1.3 Better infection-prevention designs 53 4.3.1.4 Home care & ambulatory-friendly IV devices 53 4.3.1.5 Streamlined regulatory pathways 53 4.3.1.6 Wider access & supply consistency 53 4.3.2 WHITE SPACE OPPORTUNITIES 53 4.3.2.1 Low-cost smart infusion pumps for emerging markets 53 4.3.2.2 Integrated IV ecosystem 54 4.3.2.3 Home infusion & ambulatory-first devices 54 4.3.2.4 Infection-prevention IV consumables 54 4.3.2.5 Disposable/Single-use smart components 54 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 55 4.4.1 INTERCONNECTED MARKETS 55 4.4.2 CROSS-SECTOR OPPORTUNITIES 55 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 56 4.5.1 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 56 5 INDUSTRY TRENDS 57 5.1 PORTER’S FIVE FORCES ANALYSIS 57 5.1.1 THREAT OF NEW ENTRANTS 58 5.1.2 THREAT OF SUBSTITUTES 58 5.1.3 BARGAINING POWER OF SUPPLIERS 59 5.1.4 BARGAINING POWER OF BUYERS 59 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 59 5.2 MACROECONOMIC INDICATORS 59 5.2.1 INTRODUCTION 59 5.2.2 GDP TRENDS & FORECAST 59 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 61 5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY 61 5.3 SUPPLY CHAIN ANALYSIS 61 5.4 VALUE CHAIN ANALYSIS 63 5.5 MARKET ECOSYSTEM 64 5.5.1 ROLE IN ECOSYSTEM 65 5.6 PRICING ANALYSIS 65 5.6.1 AVERAGE SELLING PRICE TREND OF IV EQUIPMENT, BY KEY PLAYER, 2023–2025 (USD) 66 5.6.2 AVERAGE SELLING PRICE TREND OF INFUSION PUMPS, BY REGION, 2023–2025 (USD) 67 5.7 TRADE ANALYSIS 68 5.7.1 IMPORT DATA (HS CODE 901890) 68 5.7.2 EXPORT DATA (HS CODE 901890) 69 5.8 REIMBURSEMENT SCENARIO 69 5.9 KEY CONFERENCES & EVENTS, 2026–2027 70 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 71 5.11 INVESTMENT & FUNDING SCENARIO 72 5.12 CASE STUDY ANALYSIS 73 5.13 IMPACT OF 2025 US TARIFFS ON IV EQUIPMENT MARKET 75 5.13.1 INTRODUCTION 75 5.13.2 KEY TARIFF RATES 76 5.13.3 PRICE IMPACT ANALYSIS 76 5.13.4 IMPACT ON COUNTRY/REGION 77 5.13.5 IMPACT ON END-USE SEGMENTS 79 5.13.5.1 Hospitals 79 5.13.5.2 Outpatient infusion & specialty clinics 79 5.13.5.3 Ambulatory surgical centers (ASCs) 79 5.13.5.4 Home care settings 79 5.13.5.5 Other end users (long-term care facilities, emergency services, and specialty clinics) 79 6 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION 80 6.1 TECHNOLOGY ANALYSIS 80 6.1.1 KEY EMERGING TECHNOLOGIES 80 6.1.1.1 Smart infusion pumps 80 6.1.1.2 Closed-loop infusion control systems 80 6.1.2 COMPLEMENTARY TECHNOLOGIES 80 6.1.2.1 Dose-error reduction systems 80 6.1.2.2 Telemedicine & remote infusion monitoring 81 6.1.3 ADJACENT TECHNOLOGIES 81 6.1.3.1 Embedded software 81 6.2 TECHNOLOGY/PRODUCT ROADMAP 82 6.2.1 NEAR TERM (2025–2027) 82 6.2.2 MID TERM (2028–2030) 82 6.2.3 LONG TERM (2030+) 82 6.3 PATENT ANALYSIS 83 6.3.1 JURISDICTION & TOP APPLICANT ANALYSIS 83 6.4 FUTURE APPLICATIONS 85 6.4.1 REMOTE & HOME-BASED INFUSION THERAPY 85 6.4.2 CLOSED-LOOP IV THERAPY & AUTOMATED DOSING 85 6.4.3 AI-DRIVEN INFUSION SAFETY & PREDICTIVE QUALITY MANAGEMENT 85 6.5 IMPACT OF AI/GEN AI ON IV EQUIPMENT MARKET 86 6.5.1 INTRODUCTION 86 6.5.2 MARKET POTENTIAL OF AI IN IV EQUIPMENT 86 6.5.3 AI USE CASES 86 6.5.4 KEY COMPANIES IMPLEMENTING AI 88 7 SUSTAINABILITY & REGULATORY LANDSCAPE 89 7.1 REGULATORY LANDSCAPE 89 7.1.1 REGULATORY FRAMEWORK 89 7.1.1.1 North America 89 7.1.1.2 Europe 89 7.1.1.3 Asia Pacific 89 7.1.1.4 Latin America 90 7.1.1.5 Middle East & Africa 90 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91 7.1.3 INDUSTRY STANDARDS 93 7.2 SUSTAINABILITY INITIATIVES 94 7.2.1 RECYCLED AND ECO-FRIENDLY MATERIALS FOR IV EQUIPMENT 94 7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 94 7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 95 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 96 8.1 KEY STAKEHOLDERS & BUYING CRITERIA 96 8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS 96 8.1.2 BUYING CRITERIA 97 8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 98 8.2.1 DECISION-MAKING PROCESS 98 8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 99 8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 99 8.2.4 MARKET PROFITABILITY 100 9 IV EQUIPMENT MARKET, BY TYPE 101 9.1 INTRODUCTION 102 9.2 IV CATHETERS 102 9.2.1 GROWING HOSPITAL ADMISSIONS AND VASCULAR ACCESS DEMAND TO DRIVE USE OF IV CATHETERS 102 9.3 INFUSION PUMPS 104 9.3.1 SHIFT TOWARD PRECISION MEDICINE AND DIGITAL SAFETY TO ACCELERATE SMART PUMP ADOPTION 104 9.4 IV ADMINISTRATION SETS & TUBING 107 9.4.1 HIGH-VOLUME THERAPY DEMAND AND SUPPLY CHAIN RESILIENCE TO DRIVE IV SET CONSUMPTION 107   9.5 SECUREMENT & STABILIZATION DEVICES 108 9.5.1 GROWING CLINICAL EMPHASIS ON LINE STABILITY AND INFECTION PREVENTION TO ELEVATE SECUREMENT DEMAND 108 9.6 NEEDLE-FREE CONNECTORS & EXTENSION SETS 110 9.6.1 NEEDLESTICK PREVENTION AND INFECTION CONTROL POLICIES TO EXPAND CONNECTOR ADOPTION 110 9.7 IV DRIP CHAMBERS 112 9.7.1 ESSENTIAL FLOW-CONTROL COMPONENTS TO SUPPORT HIGH-VOLUME GRAVITY INFUSIONS 112 9.8 OTHER IV EQUIPMENT 114 10 IV EQUIPMENT MARKET, BY APPLICATION 117 10.1 INTRODUCTION 118 10.2 MEDICATION ADMINISTRATION 118 10.2.1 ONCOLOGY (IV CHEMOTHERAPY) 120 10.2.1.1 Rising cancer burden to drive market growth 120 10.2.2 ANTIBIOTIC/ANTIMICROBIAL IV THERAPY 122 10.2.2.1 Prolonged antibiotic therapy to boost market growth 122 10.2.3 CRITICAL CARE & VASOACTIVE DRUG INFUSION 123 10.2.3.1 Demand for advanced IV pumps and compatible disposables to aid market growth 123 10.2.4 ANALGESIA/PAIN MANAGEMENT 125 10.2.4.1 Surge in chronic pain conditions to propel market growth 125 10.2.5 SEDATION & ANESTHESIA INFUSION 127 10.2.5.1 High procedural sedation demand to propel market growth 127 10.2.6 IMMUNOTHERAPY 128 10.2.6.1 Increasing use in immune-mediated conditions to support market growth 128 10.3 PARENTERAL NUTRITION (PN) 130 10.3.1 GASTROINTESTINAL DISORDERS 132 10.3.1.1 Rising GI disorders to support market growth 132 10.3.2 CRITICAL CARE NUTRITION 133 10.3.2.1 Increasing demand in ICU units to support market growth 133 10.3.3 NEONATAL & PEDIATRIC PARENTERAL NUTRITION 135 10.3.3.1 Increasing demand for neonatal lipid formulations to propel market growth 135 10.3.4 OTHER PARENTERAL NUTRITION APPLICATIONS 136 10.4 FLUID & ELECTROLYTE REPLACEMENT 138 10.4.1 GROWING DEMAND FOR FLUID AND REPLACEMENT THERAPY TO DRIVE MARKET GROWTH 138 10.5 BLOOD & BLOOD PRODUCTS TRANSFUSION 139 10.5.1 RED BLOOD CELL TRANSFUSION 141 10.5.1.1 Growing use in symptomatic anemia, acute blood loss, and perioperative blood replacement to support market growth 141 10.5.2 PLATELET TRANSFUSION 143 10.5.2.1 Growing use of standard blood administration sets to fuel growth 143 10.5.3 PLASMA TRANSFUSION 144 10.5.3.1 Wide usage in critical therapy for coagulation disorders to expand market 144 10.5.4 OTHER BLOOD & BLOOD PRODUCTS TRANSFUSION APPLICATIONS 146 10.6 DIAGNOSTIC TESTING 147 10.6.1 INCREASING DEMAND FOR DIAGNOSTIC IMAGING PROCEDURES TO AID MARKET GROWTH 147 10.7 OTHER APPLICATIONS 149 11 IV EQUIPMENT MARKET, BY END USER 151 11.1 INTRODUCTION 152 11.2 HOSPITALS 152 11.2.1 HIGH DEMAND AND COMPLEX INFUSION WORKFLOWS TO SUSTAIN HOSPITAL DOMINANCE IN IV EQUIPMENT USE 152 11.3 AMBULATORY SURGICAL CENTERS 154 11.3.1 GROWING NUMBER OF SURGICAL PROCEDURES IN ASCS TO PROPEL MARKET GROWTH 154 11.4 OUTPATIENT INFUSION & SPECIALTY CLINICS 155 11.4.1 HIGH DEMAND FOR IV CONSUMABLES AND INFUSION PUMPS TO DRIVE MARKET GROWTH 155 11.5 HOME CARE SETTINGS 157 11.5.1 EXPANSION OF HOME INFUSION THERAPY TO CREATE NEW DEMAND FOR PORTABLE IV DEVICES AND CONSUMABLES 157 11.6 OTHER END USERS 159 12 IV EQUIPMENT MARKET, BY REGION 161 12.1 INTRODUCTION 162 12.2 NORTH AMERICA 163 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 163 12.2.2 US 168 12.2.2.1 US to dominate North American IV equipment market 168 12.2.3 CANADA 171 12.2.3.1 Rising geriatric patient pool to drive market growth 171 12.3 EUROPE 175 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 175 12.3.2 GERMANY 179 12.3.2.1 Increasing healthcare expenditure to drive market growth 179 12.3.3 UK 182 12.3.3.1 Rising adoption of advanced healthcare systems to support market growth 182 12.3.4 FRANCE 186 12.3.4.1 Rising digital expansion to propel market growth 186 12.3.5 ITALY 190 12.3.5.1 Rising elderly patient pool to drive market growth 190 12.3.6 SPAIN 193 12.3.6.1 Steady modernization of healthcare system in Spain to support market growth 193 12.3.7 NETHERLANDS 197 12.3.7.1 Strong healthcare infrastructure and aging population to drive market 197 12.3.8 DENMARK 200 12.3.8.1 Well-established healthcare infrastructure to boost market 200 12.3.9 SWEDEN 203 12.3.9.1 Rising healthcare expenditure to aid market growth 203 12.3.10 REST OF EUROPE 206 12.4 ASIA PACIFIC 210 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 210 12.4.2 CHINA 215 12.4.2.1 Government support and rising disease burden to drive market growth 215 12.4.3 JAPAN 219 12.4.3.1 High healthcare expenditure, favorable reimbursement, and insurance coverage to support market growth 219 12.4.4 INDIA 223 12.4.4.1 Government initiatives to propel market growth 223 12.4.5 SOUTH KOREA 227 12.4.5.1 Rising aging population to bolster market growth 227 12.4.6 AUSTRALIA 230 12.4.6.1 Rising hospitalization rates to aid market growth 230 12.4.7 PHILIPPINES 234 12.4.7.1 Government investment and public hospital modernization to fuel demand 234 12.4.8 MALAYSIA 238 12.4.8.1 Rising healthcare investment and technological advancements to drive market 238 12.4.9 VIETNAM 241 12.4.9.1 Growing aging population and healthcare infrastructure development to fuel market 241 12.4.10 SINGAPORE 245 12.4.10.1 Advanced healthcare infrastructure and technological integration to boost market 245 12.4.11 INDONESIA 249 12.4.11.1 Rising prevalence of chronic diseases to drive market 249 12.4.12 THAILAND 253 12.4.12.1 Rising geriatric population and chronic diseases to drive market 253 12.4.13 REST OF ASIA PACIFIC 257 12.5 LATIN AMERICA 260 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 261 12.5.2 BRAZIL 264 12.5.2.1 Favorable government initiatives to propel market growth 264 12.5.3 MEXICO 268 12.5.3.1 Rising disease burden to aid market growth 268 12.5.4 ARGENTINA 272 12.5.4.1 Rapid aging population and subsequent rise in chronic diseases to boost market 272 12.5.5 COLOMBIA 276 12.5.5.1 Integration of technological advancements in hospitals & infusion therapy settings to propel market 276 12.5.6 CHILE 280 12.5.6.1 Growing focus on local infusion-therapy product manufacturers to fuel uptake 280 12.5.7 ECUADOR 284 12.5.7.1 Digital health initiatives to support market growth 284 12.5.8 PERU 288 12.5.8.1 Increasing focus on oncology therapeutics to boost market 288 12.5.9 REST OF LATIN AMERICA 292 12.6 MIDDLE EAST & AFRICA 295 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 296 12.6.2 GCC COUNTRIES 300 12.6.2.1 Kingdom of Saudi Arabia (KSA) 303 12.6.2.1.1 Favorable government initiatives to boost growth 303 12.6.2.2 United Arab Emirates (UAE) 307 12.6.2.2.1 Government strategies to drive market in UAE 307 12.6.2.3 Rest of GCC countries 311 12.6.3 REST OF MIDDLE EAST & AFRICA 314 13 COMPETITIVE LANDSCAPE 319 13.1 OVERVIEW 319 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 319 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS 319 13.3 REVENUE ANALYSIS, 2023–2025 321 13.4 GLOBAL MARKET SHARE ANALYSIS, 2025 321 13.4.1 US MARKET SHARE ANALYSIS, 2025 323 13.4.2 EUROPE MARKET SHARE ANALYSIS, 2025 323 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 324 13.5.1 STARS 324 13.5.2 EMERGING LEADERS 324 13.5.3 PERVASIVE PLAYERS 325 13.5.4 PARTICIPANTS 325 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 326 13.5.5.1 Company footprint 326 13.5.5.2 Region footprint 326 13.5.5.3 Type footprint 327 13.5.5.4 Application footprint 328 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 328 13.6.1 PROGRESSIVE COMPANIES 328 13.6.2 RESPONSIVE COMPANIES 328 13.6.3 DYNAMIC COMPANIES 329 13.6.4 STARTING BLOCKS 329 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 330 13.6.5.1 Detailed list of key startups/SMEs 330 13.6.5.2 Competitive benchmarking of key startups/SME players 330 13.7 COMPANY VALUATION & FINANCIAL METRICS 331 13.7.1 FINANCIAL METRICS 331 13.7.2 COMPANY VALUATION 331 13.8 BRAND/PRODUCT COMPARISON 332 13.9 COMPETITIVE SCENARIO 333 13.9.1 PRODUCT LAUNCHES & APPROVALS 333 13.9.2 DEALS 334 13.9.3 EXPANSIONS 335 13.9.4 OTHER DEVELOPMENTS 335 14 COMPANY PROFILES 336 14.1 KEY PLAYERS 336 14.1.1 BECTON, DICKINSON AND COMPANY 336 14.1.1.1 Business overview 336 14.1.1.2 Products offered 337 14.1.1.3 Recent developments 339 14.1.1.3.1 Product approvals 339 14.1.1.3.2 Deals 340 14.1.1.3.3 Expansions 340 14.1.1.3.4 Other developments 341 14.1.1.4 MnM view 341 14.1.1.4.1 Right to win 341 14.1.1.4.2 Strategic choices 341 14.1.1.4.3 Weaknesses & competitive threats 341 14.1.2 B. BRAUN SE 342 14.1.2.1 Business overview 342 14.1.2.2 Products offered 343 14.1.2.3 Recent developments 347 14.1.2.3.1 Product launches & approvals 347 14.1.2.3.2 Deals 347 14.1.2.4 MnM view 348 14.1.2.4.1 Right to win 348 14.1.2.4.2 Strategic choices 348 14.1.2.4.3 Weaknesses & competitive threats 348 14.1.3 BAXTER 349 14.1.3.1 Business overview 349 14.1.3.2 Products offered 350 14.1.3.3 Recent developments 351 14.1.3.3.1 Product approvals 351 14.1.3.3.2 Deals 352 14.1.3.4 MnM view 352 14.1.3.4.1 Right to win 352 14.1.3.4.2 Strategic choices 352 14.1.3.4.3 Weaknesses & competitive threats 353 14.1.4 FRESENIUS SE & CO. KGAA 354 14.1.4.1 Business overview 354 14.1.4.2 Products offered 355 14.1.4.3 Recent developments 357 14.1.4.3.1 Product approvals 357 14.1.4.3.2 Deals 357 14.1.4.4 MnM view 358 14.1.4.4.1 Right to win 358 14.1.4.4.2 Strategic choices 358 14.1.4.4.3 Weaknesses & competitive threats 358 14.1.5 ICU MEDICAL, INC. 359 14.1.5.1 Business overview 359 14.1.5.2 Products offered 360 14.1.5.3 Recent developments 362 14.1.5.3.1 Product approvals 362 14.1.5.3.2 Deals 362 14.1.5.4 MnM view 363 14.1.5.4.1 Right to win 363 14.1.5.4.2 Strategic choices 363 14.1.5.4.3 Weaknesses & competitive threats 363 14.1.6 TERUMO CORPORATION 364 14.1.6.1 Business overview 364 14.1.6.2 Products offered 365 14.1.6.3 Recent developments 366 14.1.6.3.1 Deals 366 14.1.6.3.2 Expansions 366   14.1.7 MOOG, INC. 367 14.1.7.1 Business overview 367 14.1.7.2 Products offered 368 14.1.7.2.1 Product approvals 369 14.1.8 TELEFLEX INCORPORATED 370 14.1.8.1 Business overview 370 14.1.8.2 Products offered 371 14.1.9 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 372 14.1.9.1 Business overview 372 14.1.9.2 Products offered 373 14.1.9.3 Recent developments 374 14.1.9.3.1 Product launches 374 14.1.9.3.2 Other developments 375 14.1.10 CARDINAL HEALTH 376 14.1.10.1 Business overview 376 14.1.10.2 Products offered 377 14.1.10.3 Recent developments 378 14.1.10.3.1 Expansions 378 14.1.11 AVANOS MEDICAL, INC. 379 14.1.11.1 Business overview 379 14.1.11.2 Products offered 380 14.1.12 NIPRO 381 14.1.12.1 Business overview 381 14.1.12.2 Products offered 382 14.1.12.3 Recent developments 383 14.1.12.3.1 Expansions 383 14.1.13 JMS CO., LTD. 384 14.1.13.1 Business overview 384 14.1.13.2 Products offered 385 14.1.14 VYGON 386 14.1.14.1 Business overview 386 14.1.14.2 Products offered 386 14.1.14.3 Recent developments 387 14.1.14.3.1 Deals 387 14.1.15 MICREL MEDICAL DEVICES SA 388 14.1.15.1 Business overview 388 14.1.15.2 Products offered 388 14.1.15.3 Recent developments 389 14.1.15.3.1 Deals 389 14.2 OTHER PLAYERS 390 14.2.1 ARCOMED 390 14.2.2 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD. 391 14.2.3 EITAN MEDICAL 392 14.2.4 ANGIPLAST PRIVATE LIMITED 393 14.2.5 PRIMEGUARD MEDICAL 394 14.2.6 IRADIMED CORPORATION 395 14.2.7 EPIC MEDICAL 395 14.2.8 ROMSONS 396 14.2.9 BEIJING KELLYMED CO., LTD. 397 14.2.10 INTUVIE HOLDINGS LLC 398 14.2.11 PROMED TECHNOLOGY CO., LIMITED 399 14.2.12 MEDCAPTAIN MEDICAL TECHNOLOGY CO., LTD. 400 15 RESEARCH METHODOLOGY 401 15.1 RESEARCH APPROACH 401 15.2 RESEARCH METHODOLOGY DESIGN 401 15.2.1 SECONDARY RESEARCH 402 15.2.1.1 Key data from secondary sources 403 15.2.2 PRIMARY DATA 403 15.2.2.1 Key industry insights 404 15.3 MARKET SIZE ESTIMATION 406 15.3.1 BOTTOM-UP APPROACH 411 15.4 MARKET BREAKDOWN & DATA TRIANGULATION 412 15.5 MARKET SHARE ESTIMATION 413 15.6 ASSUMPTIONS 413 15.6.1 GROWTH RATE ASSUMPTIONS 414 15.7 RISK ASSESSMENT 414 15.8 LIMITATIONS 414 15.8.1 METHODOLOGY-RELATED LIMITATIONS 414 15.8.2 SCOPE-RELATED LIMITATIONS 414 16 APPENDIX 415 16.1 DISCUSSION GUIDE 415 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 420 16.3 CUSTOMIZATION OPTIONS 422 16.3.1 COMPANY INFORMATION 422 16.3.2 GEOGRAPHIC ANALYSIS 422 16.3.3 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS 422 16.3.4 COUNTRY-LEVEL VOLUME ANALYSIS 422 16.3.5 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST 422 16.4 RELATED REPORTS 423 16.5 AUTHOR DETAILS 424
圖表清單 List of Tables & Figures
TABLE 1 IV EQUIPMENT MARKET: INCLUSIONS & EXCLUSIONS 36 TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 37 TABLE 3 IV EQUIPMENT MARKET: PORTER’S FIVE FORCES ANALYSIS 57 TABLE 4 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION) 60 TABLE 5 IV EQUIPMENT MARKET: ROLE IN ECOSYSTEM 65 TABLE 6 AVERAGE SELLING PRICE TREND OF IV EQUIPMENT, BY KEY PLAYER, 2023–2025 (USD) 66 TABLE 7 AVERAGE SELLING PRICE TREND OF INFUSION PUMPS, BY REGION, 2023–2025 (USD) 67 TABLE 8 IMPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN MEDICAL, SURGICAL, OR VETERINARY SCIENCES (HS CODE 901890), BY COUNTRY, 2020–2024 (USD THOUSAND) 68 TABLE 9 EXPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN MEDICAL, SURGICAL, OR VETERINARY SCIENCES (HS CODE 901890), BY COUNTRY, 2020–2024 (USD THOUSAND) 69 TABLE 10 IV EQUIPMENT MARKET: MAJOR CONFERENCES & EVENTS IN 2026–2027 70 TABLE 11 CASE STUDY 1: NEXT-GENERATION INTRAVENOUS (IV) INFUSION PUMPS 73 TABLE 12 CASE STUDY 2: PREVENTING IV CATHETER DISLODGMENT IN PEDIATRIC NEUROSURGERY 73 TABLE 13 CASE STUDY 3: INFUSION PUMP INTEROPERABILITY TRANSFORMS MEDICATION SAFETY 74 TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES, 2024 76 TABLE 15 KEY PRODUCT-RELATED TARIFFS EFFECTIVE 76 TABLE 16 NORTH AMERICA: IMPACT OF US TARIFFS ON CANADA 77 TABLE 17 ASIA PACIFIC: IMPACT OF US TARIFFS ON CHINA, JAPAN, AND INDIA 77 TABLE 18 EUROPE: IMPACT OF US TARIFFS ON GERMANY AND UK 78 TABLE 19 LATIN AMERICA: IMPACT OF US TARIFFS ON MEXICO 79 TABLE 20 IV EQUIPMENT MARKET: KEY PATENTS, 2023–2025 84 TABLE 21 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91 TABLE 22 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91 TABLE 23 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 TABLE 24 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 25 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 26 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF IV EQUIPMENT 97 TABLE 27 KEY BUYING CRITERIA FOR IV EQUIPMENT, BY TYPE 98 TABLE 28 IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 102 TABLE 29 COMMERCIAL IV CATHETERS AVAILABLE IN MARKET 103 TABLE 30 IV CATHETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 103 TABLE 31 COMMERCIAL INFUSION PUMPS AVAILABLE IN MARKET 105 TABLE 32 INFUSION PUMPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 105 TABLE 33 COMMERCIAL IV ADMINISTRATION SETS & TUBING AVAILABLE IN MARKET 107 TABLE 34 IV ADMINISTRATION SETS & TUBING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 107 TABLE 35 COMMERCIAL SECUREMENT & STABILIZATION DEVICES AVAILABLE IN MARKET 109 TABLE 36 SECUREMENT & STABILIZATION DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 109 TABLE 37 COMMERCIAL NEEDLE-FREE CONNECTORS & EXTENSION SETS AVAILABLE IN MARKET 111 TABLE 38 NEEDLE-FREE CONNECTORS & EXTENSION SETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 111 TABLE 39 COMMERCIAL IV DRIP CHAMBERS AVAILABLE IN MARKET 113 TABLE 40 IV DRIP CHAMBERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 113 TABLE 41 COMMERCIAL OTHER IV EQUIPMENT AVAILABLE IN MARKET 115 TABLE 42 OTHER IV EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 115 TABLE 43 IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 118 TABLE 44 IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 119 TABLE 45 IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 46 IV EQUIPMENT MARKET FOR ONCOLOGY (IV CHEMOTHERAPY), BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 47 IV EQUIPMENT MARKET FOR ANTIBIOTIC/ANTIMICROBIAL IV THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 48 IV EQUIPMENT MARKET FOR CRITICAL CARE & VASOACTIVE DRUG INFUSION, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 49 IV EQUIPMENT MARKET FOR ANALGESIA/PAIN MANAGEMENT, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 50 IV EQUIPMENT MARKET FOR SEDATION & ANESTHESIA INFUSION, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 51 IV EQUIPMENT MARKET FOR IMMUNOTHERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 52 IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION (PN), BY TYPE, 2024–2031 (USD MILLION) 130 TABLE 53 IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION (PN), BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 54 IV EQUIPMENT MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 55 IV EQUIPMENT MARKET FOR CRITICAL CARE NUTRITION, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 56 IV EQUIPMENT MARKET FOR NEONATAL & PEDIATRIC PARENTERAL NUTRITION, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 57 IV EQUIPMENT MARKET FOR OTHER PARENTERAL NUTRITION APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 58 IV EQUIPMENT MARKET FOR FLUID & ELECTROLYTE REPLACEMENT, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 59 IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 140 TABLE 60 IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 61 IV EQUIPMENT MARKET FOR RED BLOOD CELL TRANSFUSION, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 62 IV EQUIPMENT MARKET FOR PLATELET TRANSFUSION, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 63 IV EQUIPMENT MARKET FOR PLASMA TRANSFUSION, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 64 IV EQUIPMENT MARKET FOR OTHER BLOOD & BLOOD PRODUCTS TRANSFUSION APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 65 IV EQUIPMENT MARKET FOR DIAGNOSTIC TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 66 IV EQUIPMENT MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 67 IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 152 TABLE 68 IV EQUIPMENT MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 69 IV EQUIPMENT MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 70 IV EQUIPMENT MARKET FOR OUTPATIENT INFUSION & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 71 IV EQUIPMENT MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 72 IV EQUIPMENT MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 73 IV EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 162 TABLE 74 IV CATHETERS MARKET, BY REGION, 2024–2031 (MILLION UNITS) 162 TABLE 75 INFUSION PUMPS MARKET, BY REGION, 2024–2031 (MILLION UNITS) 163 TABLE 76 IV ADMINISTRATION SETS & TUBING MARKET, BY REGION, 2024–2031 (MILLION UNITS) 163 TABLE 77 NORTH AMERICA: IV EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 78 NORTH AMERICA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 165 TABLE 79 NORTH AMERICA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 166 TABLE 80 NORTH AMERICA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 166 TABLE 81 NORTH AMERICA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 167 TABLE 82 NORTH AMERICA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 167 TABLE 83 NORTH AMERICA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 168 TABLE 84 US: KEY MACROECONOMIC INDICATORS 168 TABLE 85 US: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 169 TABLE 86 US: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 169 TABLE 87 US: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 170 TABLE 88 US: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 170 TABLE 89 US: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 171 TABLE 90 US: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 171 TABLE 91 CANADA: KEY MACROECONOMIC INDICATORS 172 TABLE 92 CANADA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 172 TABLE 93 CANADA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 173 TABLE 94 CANADA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 173 TABLE 95 CANADA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 174 TABLE 96 CANADA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 174 TABLE 97 CANADA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 175 TABLE 98 EUROPE: IV EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 99 EUROPE: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 176 TABLE 100 EUROPE: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 177 TABLE 101 EUROPE: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 177 TABLE 102 EUROPE: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 178 TABLE 103 EUROPE: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 178 TABLE 104 EUROPE: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 179 TABLE 105 GERMANY: KEY MACROECONOMIC INDICATORS 179 TABLE 106 GERMANY: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 180 TABLE 107 GERMANY: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 180 TABLE 108 GERMANY: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 181 TABLE 109 GERMANY: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 181 TABLE 110 GERMANY: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 182 TABLE 111 GERMANY: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 182 TABLE 112 UK: KEY MACROECONOMIC INDICATORS 183 TABLE 113 UK: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 184 TABLE 114 UK: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 184 TABLE 115 UK: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 185 TABLE 116 UK: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 185 TABLE 117 UK: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 118 UK: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 186 TABLE 119 FRANCE: KEY MACROECONOMIC INDICATORS 187 TABLE 120 FRANCE: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 187 TABLE 121 FRANCE : IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 188 TABLE 122 FRANCE : IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 188 TABLE 123 FRANCE: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 189 TABLE 124 FRANCE: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 189 TABLE 125 FRANCE: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 190 TABLE 126 ITALY: KEY MACROECONOMIC INDICATORS 190 TABLE 127 ITALY: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 128 ITALY: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 191 TABLE 129 ITALY: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 192 TABLE 130 ITALY: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 192 TABLE 131 ITALY: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 193 TABLE 132 ITALY: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 193 TABLE 133 SPAIN: KEY MACROECONOMIC INDICATORS 194 TABLE 134 SPAIN: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 135 SPAIN: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 195 TABLE 136 SPAIN: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 195 TABLE 137 SPAIN: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 196 TABLE 138 SPAIN: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 196 TABLE 139 SPAIN: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 197 TABLE 140 NETHERLANDS: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 198 TABLE 141 NETHERLANDS: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 198 TABLE 142 NETHERLANDS: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 143 NETHERLANDS: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 144 NETHERLANDS: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 200 TABLE 145 NETHERLANDS: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 200 TABLE 146 DENMARK: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 201 TABLE 147 DENMARK: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 201 TABLE 148 DENMARK: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 202 TABLE 149 DENMARK: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 202 TABLE 150 DENMARK: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 151 DENMARK: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 203 TABLE 152 SWEDEN: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 153 SWEDEN: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 204 TABLE 154 SWEDEN: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 205 TABLE 155 SWEDEN: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 205 TABLE 156 SWEDEN: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 206 TABLE 157 SWEDEN: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 206 TABLE 158 REST OF EUROPE: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 207 TABLE 159 REST OF EUROPE: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 207 TABLE 160 REST OF EUROPE: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 161 REST OF EUROPE: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 162 REST OF EUROPE: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 163 REST OF EUROPE: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 209 TABLE 164 ASIA PACIFIC: IV EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212 TABLE 165 ASIA PACIFIC: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 212 TABLE 166 ASIA PACIFIC: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 213 TABLE 167 ASIA PACIFIC: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 213 TABLE 168 ASIA PACIFIC: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 169 ASIA PACIFIC: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 170 ASIA PACIFIC: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 215 TABLE 171 CHINA: KEY MACROECONOMIC INDICATORS 216 TABLE 172 CHINA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 173 CHINA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 217 TABLE 174 CHINA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 217 TABLE 175 CHINA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 218 TABLE 176 CHINA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 218 TABLE 177 CHINA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 219 TABLE 178 JAPAN: KEY MACROECONOMIC INDICATORS 220 TABLE 179 JAPAN: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 180 JAPAN: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 221 TABLE 181 JAPAN: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 182 JAPAN: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 183 JAPAN: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 184 JAPAN: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 223 TABLE 185 INDIA: KEY MACROECONOMIC INDICATORS 224 TABLE 186 INDIA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 187 INDIA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 225 TABLE 188 INDIA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 189 INDIA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 226 TABLE 190 INDIA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 226 TABLE 191 INDIA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 227 TABLE 192 SOUTH KOREA: KEY MACROECONOMIC INDICATORS 227 TABLE 193 SOUTH KOREA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 228 TABLE 194 SOUTH KOREA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 228 TABLE 195 SOUTH KOREA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 196 SOUTH KOREA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 197 SOUTH KOREA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 230 TABLE 198 SOUTH KOREA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 230 TABLE 199 AUSTRALIA: KEY MACROECONOMIC INDICATORS 231 TABLE 200 AUSTRALIA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 231 TABLE 201 AUSTRALIA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 232 TABLE 202 AUSTRALIA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 232 TABLE 203 AUSTRALIA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 204 AUSTRALIA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 205 AUSTRALIA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 234 TABLE 206 PHILIPPINES: KEY MACROECONOMIC INDICATORS 235 TABLE 207 PHILIPPINES: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 208 PHILIPPINES: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 236 TABLE 209 PHILIPPINES: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 210 PHILIPPINES: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 237 TABLE 211 PHILIPPINES: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 237 TABLE 212 PHILIPPINES: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 238 TABLE 213 MALAYSIA: KEY MACROECONOMIC INDICATORS 238 TABLE 214 MALAYSIA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 215 MALAYSIA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 239 TABLE 216 MALAYSIA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 217 MALAYSIA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 218 MALAYSIA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 219 MALAYSIA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 241 TABLE 220 VIETNAM: KEY MACROECONOMIC INDICATORS 242 TABLE 221 VIETNAM: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 222 VIETNAM: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 243 TABLE 223 VIETNAM: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 224 VIETNAM: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 225 VIETNAM: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 226 VIETNAM: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 245 TABLE 227 SINGAPORE: KEY MACROECONOMIC INDICATORS 246 TABLE 228 SINGAPORE: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 229 SINGAPORE: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 247 TABLE 230 SINGAPORE: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 231 SINGAPORE: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 232 SINGAPORE: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 233 SINGAPORE: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 249 TABLE 234 INDONESIA: KEY MACROECONOMIC INDICATORS 250 TABLE 235 INDONESIA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 236 INDONESIA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 251 TABLE 237 INDONESIA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 238 INDONESIA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 239 INDONESIA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 240 INDONESIA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 253 TABLE 241 THAILAND: KEY MACROECONOMIC INDICATORS 254 TABLE 242 THAILAND: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 243 THAILAND: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 255 TABLE 244 THAILAND: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 245 THAILAND: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 246 THAILAND: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 247 THAILAND: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 257 TABLE 248 REST OF ASIA PACIFIC: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 249 REST OF ASIA PACIFIC: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 258 TABLE 250 REST OF ASIA PACIFIC: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 251 REST OF ASIA PACIFIC: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 252 REST OF ASIA PACIFIC: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 253 REST OF ASIA PACIFIC: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 260 TABLE 254 LATIN AMERICA: IV EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 261 TABLE 255 LATIN AMERICA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 256 LATIN AMERICA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 262 TABLE 257 LATIN AMERICA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 258 LATIN AMERICA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 259 LATIN AMERICA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 264 TABLE 260 LATIN AMERICA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 264 TABLE 261 BRAZIL: KEY MACROECONOMIC INDICATORS 265 TABLE 262 BRAZIL: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 263 BRAZIL: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 266 TABLE 264 BRAZIL: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 265 BRAZIL: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 266 BRAZIL: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 267 BRAZIL: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 268 TABLE 268 MEXICO: KEY MACROECONOMIC INDICATORS 269 TABLE 269 MEXICO: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 270 MEXICO: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 270 TABLE 271 MEXICO: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 272 MEXICO: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 273 MEXICO: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 274 MEXICO: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 272 TABLE 275 ARGENTINA: KEY MACROECONOMIC INDICATORS 273 TABLE 276 ARGENTINA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 273 TABLE 277 ARGENTINA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 274 TABLE 278 ARGENTINA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 274 TABLE 279 ARGENTINA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 280 ARGENTINA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 281 ARGENTINA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 276 TABLE 282 COLOMBIA: KEY MACROECONOMIC INDICATORS 277 TABLE 283 COLOMBIA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 284 COLOMBIA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 278 TABLE 285 COLOMBIA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 278 TABLE 286 COLOMBIA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 287 COLOMBIA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 288 COLOMBIA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 280 TABLE 289 CHILE: KEY MACROECONOMIC INDICATORS 281 TABLE 290 CHILE: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 291 CHILE: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 282 TABLE 292 CHILE: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 293 CHILE: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 294 CHILE: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 295 CHILE: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 284 TABLE 296 ECUADOR: KEY MACROECONOMIC INDICATORS 285 TABLE 297 ECUADOR: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 285 TABLE 298 ECUADOR: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 286 TABLE 299 ECUADOR: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 286 TABLE 300 ECUADOR: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 301 ECUADOR: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 302 ECUADOR: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 288 TABLE 303 PERU: KEY MACROECONOMIC INDICATORS 289 TABLE 304 PERU: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 289 TABLE 305 PERU: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 290 TABLE 306 PERU: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 307 PERU: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 308 PERU: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 309 PERU: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 292 TABLE 310 REST OF LATIN AMERICA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 311 REST OF LATIN AMERICA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 293 TABLE 312 REST OF LATIN AMERICA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 294 TABLE 313 REST OF LATIN AMERICA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 294 TABLE 314 REST OF LATIN AMERICA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 295 TABLE 315 REST OF LATIN AMERICA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 295 TABLE 316 MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 297 TABLE 317 MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 318 MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 298 TABLE 319 MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 320 MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 321 MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 322 MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 300 TABLE 323 GCC COUNTRIES: IV EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 300 TABLE 324 GCC COUNTRIES: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 325 GCC COUNTRIES: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 301 TABLE 326 GCC COUNTRIES: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 327 GCC COUNTRIES: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 328 GCC COUNTRIES: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 329 GCC COUNTRIES: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 303 TABLE 330 KINGDOM OF SAUDI ARABIA: KEY MACROECONOMIC INDICATORS 304 TABLE 331 KINGDOM OF SAUDI ARABIA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 305 TABLE 332 KINGDOM OF SAUDI ARABIA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 305 TABLE 333 KINGDOM OF SAUDI ARABIA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 334 KINGDOM OF SAUDI ARABIA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 335 KINGDOM OF SAUDI ARABIA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 307 TABLE 336 KINGDOM OF SAUDI ARABIA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 307 TABLE 337 UAE: KEY MACROECONOMIC INDICATORS 308 TABLE 338 UAE: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 308 TABLE 339 UAE: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 309 TABLE 340 UAE: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 341 UAE: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 342 UAE: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 343 UAE: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 311 TABLE 344 REST OF GCC COUNTRIES: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 312 TABLE 345 REST OF GCC COUNTRIES: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 312 TABLE 346 REST OF GCC COUNTRIES: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 347 REST OF GCC COUNTRIES: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 348 REST OF GCC COUNTRIES: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 349 REST OF GCC COUNTRIES: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 314 TABLE 350 REST OF MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 351 REST OF MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 316 TABLE 352 REST OF MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET FOR MEDICATION ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 353 REST OF MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET FOR PARENTERAL NUTRITION, BY TYPE, 2024–2031 (USD MILLION) 317 TABLE 354 REST OF MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET FOR BLOOD & BLOOD PRODUCTS TRANSFUSION, BY TYPE, 2024–2031 (USD MILLION) 317 TABLE 355 REST OF MIDDLE EAST & AFRICA: IV EQUIPMENT MARKET, BY END USER, 2024–2031 (USD MILLION) 318 TABLE 356 OVERVIEW OF STRATEGIES ADOPTED BY KEY IV EQUIPMENT MANUFACTURING COMPANIES 319 TABLE 357 GLOBAL IV EQUIPMENT MARKET: DEGREE OF COMPETITION 322 TABLE 358 IV EQUIPMENT MARKET: REGION FOOTPRINT 326 TABLE 359 IV EQUIPMENT MARKET: TYPE FOOTPRINT 327 TABLE 360 IV EQUIPMENT MARKET: APPLICATION FOOTPRINT 328 TABLE 361 IV EQUIPMENT MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 330 TABLE 362 IV EQUIPMENT MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS 330 TABLE 363 IV EQUIPMENT MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–DECEMBER 2025 333 TABLE 364 IV EQUIPMENT MARKET: DEALS, JANUARY 2022–DECEMBER 2025 334 TABLE 365 IV EQUIPMENT MARKET: EXPANSIONS, JANUARY 2022–DECEMBER 2025 335 TABLE 366 IV EQUIPMENT MARKET: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 335 TABLE 367 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 336 TABLE 368 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 337 TABLE 369 BECTON, DICKINSON AND COMPANY: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 339 TABLE 370 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2022–DECEMBER 2025 340 TABLE 371 BECTON, DICKINSON AND COMPANY: EXPANSIONS, JANUARY 2022–DECEMBER 2025 340 TABLE 372 BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 341 TABLE 373 B. BRAUN SE: COMPANY OVERVIEW 342 TABLE 374 B. BRAUN SE: PRODUCTS OFFERED 343 TABLE 375 B. BRAUN SE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–NOVEMBER 2025 347 TABLE 376 B. BRAUN SE: DEALS, JANUARY 2022−DECEMBER 2025 347 TABLE 377 BAXTER: COMPANY OVERVIEW 349 TABLE 378 BAXTER: PRODUCTS OFFERED 350 TABLE 379 BAXTER: PRODUCT APPROVALS, JANUARY 2022−NOVEMBER 2025 351 TABLE 380 BAXTER: DEALS, JANUARY 2022−NOVEMBER 2025 352 TABLE 381 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW 354 TABLE 382 FRESENIUS SE & CO. KGAA: PRODUCTS OFFERED 355 TABLE 383 FRESENIUS SE & CO. KGAA: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 357 TABLE 384 FRESENIUS SE & CO. KGAA: DEALS, JANUARY 2022–DECEMBER 2025 357 TABLE 385 ICU MEDICAL, INC.: COMPANY OVERVIEW 359 TABLE 386 ICU MEDICAL, INC.: PRODUCTS OFFERED 360 TABLE 387 ICU MEDICAL, INC.: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 362 TABLE 388 ICU MEDICAL, INC.: DEALS, JANUARY 2022–DECEMBER 2025 362 TABLE 389 TERUMO CORPORATION: COMPANY OVERVIEW 364 TABLE 390 TERUMO CORPORATION: PRODUCTS OFFERED 365 TABLE 391 TERUMO CORPORATION: DEALS, JANUARY 2022–DECEMBER 2025 366 TABLE 392 TERUMO CORPORATION: EXPANSIONS, JANUARY 2022–DECEMBER 2025 366 TABLE 393 MOOG INC.: COMPANY OVERVIEW 367 TABLE 394 MOOG INC.: PRODUCTS OFFERED 368 TABLE 395 MOOG INC.: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 369 TABLE 396 TELEFLEX INCORPORATED: COMPANY OVERVIEW 370 TABLE 397 TELEFLEX INCORPORATED: PRODUCTS OFFERED 371 TABLE 398 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 372 TABLE 399 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED 373 TABLE 400 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCT LAUNCHES, JANUARY 2022–DECEMBER 2025 374 TABLE 401 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 375 TABLE 402 CARDINAL HEALTH: COMPANY OVERVIEW 376 TABLE 403 CARDINAL HEALTH: PRODUCTS OFFERED 377 TABLE 404 CARDINAL HEALTH: EXPANSIONS, JANUARY 2022–DECEMBER 2025 378 TABLE 405 AVANOS MEDICAL, INC.: COMPANY OVERVIEW 379 TABLE 406 AVANOS MEDICAL, INC.: PRODUCTS OFFERED 380 TABLE 407 NIPRO: COMPANY OVERVIEW 381 TABLE 408 NIPRO: PRODUCTS OFFERED 382 TABLE 409 NIPRO: EXPANSIONS, JANUARY 2022–DECEMBER 2025 383 TABLE 410 JMS CO., LTD.: COMPANY OVERVIEW 384 TABLE 411 JMS CO., LTD.: PRODUCTS OFFERED 385 TABLE 412 VYGON: COMPANY OVERVIEW 386 TABLE 413 VYGON: PRODUCTS OFFERED 386 TABLE 414 VYGON: DEALS, JANUARY 2022–DECEMBER 2025 387 TABLE 415 MICREL MEDICAL DEVICES SA: COMPANY OVERVIEW 388 TABLE 416 MICREL MEDICAL DEVICES SA: PRODUCTS OFFERED 388 TABLE 417 MICREL MEDICAL DEVICES SA: DEALS, JANUARY 2022–DECEMBER 2025 389 TABLE 418 ARCOMED: COMPANY OVERVIEW 390 TABLE 419 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.: COMPANY OVERVIEW 391 TABLE 420 EITAN MEDICAL: COMPANY OVERVIEW 392 TABLE 421 ANGIPLAST PRIVATE LIMITED: COMPANY OVERVIEW 393 TABLE 422 PRIMEGUARD MEDICAL: COMPANY OVERVIEW 394 TABLE 423 IRADIMED CORPORATION: COMPANY OVERVIEW 395 TABLE 424 EPIC MEDICAL: COMPANY OVERVIEW 395 TABLE 425 ROMSONS: COMPANY OVERVIEW 396 TABLE 426 BEIJING KELLYMED CO., LTD.: COMPANY OVERVIEW 397 TABLE 427 INTUVIE HOLDINGS LLC: COMPANY OVERVIEW 398 TABLE 428 PROMED TECHNOLOGY CO., LIMITED: COMPANY OVERVIEW 399 TABLE 429 MEDCAPTAIN MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 400 TABLE 430 RISK ASSESSMENT: IV EQUIPMENT MARKET 414 FIGURE 1 IV EQUIPMENT MARKET: SEGMENTS CONSIDERED & GEOGRAPHICAL SCOPE 35 FIGURE 2 IV EQUIPMENT MARKET: YEARS CONSIDERED 37 FIGURE 3 MARKET SCENARIO 40 FIGURE 4 GLOBAL IV EQUIPMENT MARKET, 2024–2031 41 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IV EQUIPMENT MARKET, 2022–2025 41 FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF IV EQUIPMENT MARKET 42 FIGURE 7 HIGH-GROWTH SEGMENTS IN IV EQUIPMENT MARKET, 2026–2031 43 FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN IV EQUIPMENT MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 44 FIGURE 9 GROWING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH 45 FIGURE 10 HOSPITALS SEGMENT IN ASIA PACIFIC REGION ACCOUNTED FOR LARGEST SHARE IN 2025 46 FIGURE 11 CHINA TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD 47 FIGURE 12 IV EQUIPMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48 FIGURE 13 IV EQUIPMENT MARKET: PORTER'S FIVE FORCES ANALYSIS 58 FIGURE 14 IV EQUIPMENT MARKET: SUPPLY CHAIN ANALYSIS 62 FIGURE 15 IV EQUIPMENT MARKET: VALUE CHAIN ANALYSIS 63 FIGURE 16 IV EQUIPMENT MARKET ECOSYSTEM 64 FIGURE 17 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 71 FIGURE 18 INVESTMENT & FUNDING SCENARIO FOR IV EQUIPMENT MARKET PLAYERS 72 FIGURE 19 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR INFUSION PUMP PATENTS (JANUARY 2014–DECEMBER 2025) 83 FIGURE 20 IV EQUIPMENT MARKET: AI USE CASES 87 FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IV EQUIPMENT 96 FIGURE 22 KEY BUYING CRITERIA FOR IV EQUIPMENT, BY TYPE 97 FIGURE 23 NORTH AMERICA: IV EQUIPMENT MARKET SNAPSHOT 164 FIGURE 24 ASIA PACIFIC: IV EQUIPMENT MARKET SNAPSHOT 211 FIGURE 25 REVENUE ANALYSIS OF KEY PLAYERS IN IV EQUIPMENT MARKET, 2023–2025 321 FIGURE 26 GLOBAL MARKET SHARE ANALYSIS OF KEY PLAYERS IN IV EQUIPMENT MARKET, 2025 322 FIGURE 27 US MARKET SHARE ANALYSIS OF KEY PLAYERS IN IV EQUIPMENT MARKET, 2025 323 FIGURE 28 EUROPE MARKET SHARE ANALYSIS OF KEY PLAYERS IN IV EQUIPMENT MARKET, 2025 323 FIGURE 29 IV EQUIPMENT MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 325 FIGURE 30 IV EQUIPMENT MARKET: COMPANY FOOTPRINT 326 FIGURE 31 IV EQUIPMENT MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 329 FIGURE 32 EV/EBITDA OF KEY VENDORS 331 FIGURE 33 YEAR-TO-DATE PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 331 FIGURE 34 IV EQUIPMENT MARKET: BRAND/PRODUCT COMPARISON 332 FIGURE 35 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2025) 337 FIGURE 36 B. BRAUN SE: COMPANY SNAPSHOT (2024) 343 FIGURE 37 BAXTER: COMPANY SNAPSHOT (2024) 350 FIGURE 38 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2024) 355 FIGURE 39 ICU MEDICAL, INC.: COMPANY SNAPSHOT (2024) 360 FIGURE 40 TERUMO CORPORATION: COMPANY SNAPSHOT (2024) 365 FIGURE 41 MOOG INC.: COMPANY SNAPSHOT (2024) 368 FIGURE 42 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2024) 371 FIGURE 43 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2024) 373 FIGURE 44 CARDINAL HEALTH: COMPANY SNAPSHOT (2025) 377 FIGURE 45 AVANOS MEDICAL, INC.: COMPANY SNAPSHOT (2024) 380 FIGURE 46 NIPRO: COMPANY SNAPSHOT (2024) 382 FIGURE 47 JMS CO., LTD.: COMPANY SNAPSHOT (2024) 385 FIGURE 48 IV EQUIPMENT MARKET: RESEARCH DESIGN 401 FIGURE 49 PRIMARY SOURCES 403 FIGURE 50 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE) 405 FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (DEMAND SIDE) 405 FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 406 FIGURE 53 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 407 FIGURE 54 REVENUE SHARE ANALYSIS ILLUSTRATION: BECTON, DICKINSON AND COMPANY 407 FIGURE 55 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF IV EQUIPMENT MARKET (2025–2030) 409 FIGURE 56 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 410 FIGURE 57 TOP-DOWN APPROACH 410 FIGURE 58 BOTTOM-UP APPROACH 411 FIGURE 59 MARKET DATA TRIANGULATION METHODOLOGY 412

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們